key: cord-1005702-amz0odpb
authors: Frank, Stephan
title: Catch me if you can: SARS-CoV-2 detection in brains of deceased patients with COVID-19
date: 2020-10-05
journal: Lancet Neurol
DOI: 10.1016/s1474-4422(20)30371-9
sha: 6badf7d126c3bc1eefec3045327108f5b8355ca0
doc_id: 1005702
cord_uid: amz0odpb

nan

In the American biographical crime film Catch Me If You Can, FBI agent Carl Hanratty goes all out to catch the notorious impostor and cheque counterfeiter Frank Abagnale Jr. Hanratty's dogged pursuit of the culprit bears striking resemblance to current COVID-19 research efforts to find evidence of changes that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection might leave in the brain. In The Lancet Neurology, Jakob Matschke and colleagues 1 give a detailed account of the histological alterations related to COVID-19 in the CNS. Through meticulous detective work, they mapped the brain's immunoinflammatory response to viral infection and detected SARS-CoV-2 protein expression in a substantial percentage of autoptic brains of patients with COVID-19.

Matschke and colleagues analysed 43 brains from a large cohort of patients who died with COVID-19, 2 focusing on inflammatory changes and detection of SARS-CoV-2. To find out which CNS cell types are prone to SARS-CoV-2 infection, the authors screened gene expression datasets for signatures related to viral entry and persistence. Their in-silico analysis showed high expres sion of angiotensin-converting enzyme 2 (ACE2) in oligodendrocytes and of transmembrane serine proteases 2 and 4 (TMPRSS2 and TMPRSS4) in neurons-genes that code for proteins crucially implicated in SARS-CoV-2 host-cell entry (ACE2) and proteolytic priming of the virus-decorating spikes (TMPRSS2). 3 Interestingly, a study using human brain organoids, published in September, 2020, 4 showed that SARS-CoV-2 can readily infect and kill neurons. The neuronal cell death upon viral infection was preceded by aberrant intraneuronal localisa tion and hyperphosphorylation of Tau protein, 4 similar to the pathogenesis of Alzheimer's disease and other neurodegenerative diseases.

Matschke and colleagues used quantitative RT-PCR (qRT-PCR) and immunohistochemistry with antibodies against nucleocapsid and spike proteins to detect SARS-CoV-2. Whereas viral RNA was detected in 48% of cases, viral protein detection was positive in 40%. Overall, the authors found SARS-CoV-2, either viral RNA or viral protein (or both), in 51% of the brains investi gated. Remarkably, SARS-CoV-2 presence did not correlate with the severity of neuropathological alterations. While the replicative and infective potential of the viral RNA remains unclear, the in-situ detection of SARS-CoV-2 proteins is an important finding, as it confirms the presence of the virus in the brain. In this context, con cerns 5,6 that the comparably low viral genome levels detec table by qRT-PCR in brain tissue might be blood-derived deserve mention.

Of note, the authors found virus protein expression to be confined to the medulla oblongata and to cranial nerves originating from the lower brainstem (most likely glossopharyngeal or vagal nerve). Considering the capability of SARS-CoV-2 to infect human gut enterocytes as well as pneumocytes, 7,8 this finding is of particular interest, warranting future investigations of vagal nerve tissue as a potential viral CNS access route in COVID-19.

The study also identified pronounced, brainstemaccentuated microglia activation, confirming previous work. 5 As these brain-resident macrophage-like innate immune cells are highly heterogeneous with regard to gene expression, regional abundance, and per haps func tions, 9 it seems worth testing whether micro glia activated in a COVID-19 context correspond to a specific sub type, 10 expressing sets of genes reflective of particular func tional states.

Given the complex pathophysiology of COVID-19, any autopsy study is bound to have limitations (varying postmortem intervals, incomplete or lacking clinical data, etc) and the present study is no exception in that regard. Confounding factors, such as the multiple comorbidities present among older patients with COVID-19 and, equally important, common COVID-19 treatment modalities, such as invasive ventilation (which might promote cerebral microbleeds) or dexamethasone medication (known to modulate immune responses), have to be con sidered when interpreting neuropathological findings. In the context of dexamethasone, it is unfortunate that no data on steroid medication were used to investigate correlations between some of the findings. Likewise, in the absence of appropriate control cohorts, it remains unclear to what extent microglia activation and brain infiltration by cyto toxic T-lymphocytes represent COVID-19-specific findings. Both sparse lymphocytic infiltrates and microglia activa tion were recently documented in the brains of indivi duals without COVID-19, and they appeared to be particularly pronounced in septic cases. 5 At a time when a potential second wave of infections is increasingly becoming of global concern, the question of whether the neuropathological alterations in COVID-19 directly result from SARS-CoV-2 brain infection as opposed to reflecting sequelae of an overstimulated systemic immune response is of high clinical importance. Whereas the first scenario would support the use of remdesevir or other antivirals, anti-inflammatory modalities appear to be the treatment of choice once damaging immunoinflammatory mechanisms take over. Teasing apart these fundamentally different scenarios is an ongoing task for neuropathology experts. The work by Matschke and colleagues 1 represents an important step towards navigating the complex pathophysiology of COVID-19 in the brain. Just like agent Hanratty, the authors have done a superb job closing in on the culprit. SF reports grants from the Botnar Research Centre for Child Health.

Division of Neuropathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, CH-4031 Basel, Switzerland

Neuropathology of patients with COVID-19 in Germany: a post-mortem case series

Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

SARS-CoV-2 targets neurons of 3D human brain organoids

Correlates of critical illness-related encephalopathy predominate postmortem COVID-19 neuropathology

Neuropathological features of COVID-19

SARS-CoV-2 productively infects human gut enterocytes

In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19

Microglia Heterogeneity in the Single-Cell Era

Human microglia regional heterogeneity and phenotypes determined by multiplexed single-cell mass cytometry